<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Midlife Health</journal-id><journal-id journal-id-type="iso-abbrev">J Midlife Health</journal-id><journal-id journal-id-type="pmc-domain-id">1548</journal-id><journal-id journal-id-type="pmc-domain">jmidhlth</journal-id><journal-id journal-id-type="publisher-id">JMH</journal-id><journal-id journal-id-type="publisher-id">J Mid-life Health</journal-id><journal-title-group><journal-title>Journal of Mid-Life Health</journal-title></journal-title-group><issn pub-type="ppub">0976-7800</issn><issn pub-type="epub">0976-7819</issn><publisher><publisher-name>Wolters Kluwer -- Medknow Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431698</article-id><article-id pub-id-type="pmcid-ver">PMC12431698.1</article-id><article-id pub-id-type="pmcaid">12431698</article-id><article-id pub-id-type="pmcaiid">12431698</article-id><article-id pub-id-type="doi">10.4103/jmh.jmh_102_25</article-id><article-id pub-id-type="publisher-id">JMH-16-309</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Expression of Programmed Cell Death Ligand 1 and Mismatch Repair Status in Ovarian Carcinomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hariprasad</surname><given-names initials="M">Madhubala</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rao</surname><given-names initials="M">Meenakshi</given-names></name><xref rid="aff2" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elhence</surname><given-names initials="PA">Poonam Abhay</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bharti</surname><given-names initials="JN">Jyotsna Naresh</given-names></name><xref rid="aff3" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singh</surname><given-names initials="P">Pratibha</given-names></name><xref rid="aff4" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yadav</surname><given-names initials="G">Garima</given-names></name><xref rid="aff4" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nalwa</surname><given-names initials="A">Aasma</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramalingam</surname><given-names initials="H">Hariprasad</given-names></name><xref rid="aff5" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goel</surname><given-names initials="AD">Akhil Dhanesh</given-names></name><xref rid="aff6" ref-type="aff">5</xref></contrib></contrib-group><aff id="aff1">Department of Histopathology, Northampton General Hospital, Northampton, United Kingdom</aff><aff id="aff2"><label>1</label>Department of Pathology and Lab Medicine, AIIMS, Jodhpur, Rajasthan, India</aff><aff id="aff3"><label>2</label>Department of Pathology and Lab Medicine, AIIMS, Mangalagiri, Andhra Pradesh, India</aff><aff id="aff4"><label>3</label>Department of Obstetrics and Gynaecology, AIIMS, Jodhpur, Rajasthan, India</aff><aff id="aff5"><label>4</label>Department of Anaesthetics and Critical Care, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom</aff><aff id="aff6"><label>5</label>Department of Community Medicine and Family Medicine, AIIMS, Jodhpur, Rajasthan, India</aff><author-notes><corresp id="cor1"><bold><italic toggle="yes">Address for correspondence:</italic></bold> Dr. Meenakshi Rao, Department Pathology and Lab Medicine, AIIMS, Jodhpur, Rajasthan, India. E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="drmeenakshirao@gmail.com">drmeenakshirao@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><volume>16</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">496819</issue-id><fpage>309</fpage><lpage>314</lpage><history><date date-type="received"><day>05</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>20</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>01</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 16:25:51.440"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2025 Journal of Mid-life Health</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JMH-16-309.pdf"/><abstract><title>A<sc>BSTRACT</sc></title><sec><title>Background:</title><p>Ovarian carcinoma is the third most common gynecological malignancy among women in India, with a poor prognosis despite advancements in treatment modalities. Immunotherapy, particularly the use of programd cell death ligand 1 (PD-L1) checkpoint inhibitors, has emerged as a promising approach. This study investigates the relationship between PD-L1 expression, mismatch repair (MMR) status, and clinicopathological features in epithelial ovarian carcinoma (EOC).</p></sec><sec><title>Materials and Methods:</title><p>A cohort of 50 EOC cases was analyzed for PD-L1 expression in tumor cells and tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). MMR status was also assessed through IHC. Statistical correlations between PD-L1 expression, MMR deficiency (dMMR), and clinicopathological parameters were evaluated.</p></sec><sec><title>Results:</title><p>PD-L1 expression in tumor cells and TILs was observed in 20% and 14% of cases, respectively. PD-L1 expression in tumor cells was absent in most advanced-stage tumors (stages III and IV) and cases with extraovarian spread. dMMR was identified in 30% (<italic toggle="yes">n</italic> = 15) of cases, predominantly in higher-stage tumors with extraovarian spread and significant TIL presence (<italic toggle="yes">P</italic> = 0.007). However, PD-L1 expression in tumor cells and TILs was absent in 86.7% and 80% of dMMR cases, respectively. No significant association was found between dMMR status and PD-L1 expression in EOC.</p></sec><sec><title>Conclusion:</title><p>PD-L1 expression in tumor cells is predominantly observed in early-stage EOC, suggesting its potential as a prognostic marker and therapeutic target. Although dMMR status correlates with advanced-stage disease and TIL presence, it does not significantly influence PD-L1 expression in EOC. These findings highlight the importance of routinely assessing PD-L1 and MMR status to guide immunotherapeutic strategies in ovarian carcinoma.</p></sec></abstract><kwd-group><title>K<sc>EYWORDS:</sc></title><kwd><italic toggle="yes">Epithelial ovarian carcinoma</italic></kwd><kwd><italic toggle="yes">immunotherapy</italic></kwd><kwd><italic toggle="yes">mismatch repair deficiency</italic></kwd><kwd><italic toggle="yes">ovarian carcinoma</italic></kwd><kwd><italic toggle="yes">programmed cell death ligand 1 expression</italic></kwd><kwd><italic toggle="yes">tumor-infiltrating lymphocytes</italic></kwd></kwd-group><funding-group><funding-statement>
Rs. 50,000/- (Rupees fifty thousand only) received from AIIMS, Jodhpur.
</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>I<sc>NTRODUCTION</sc></title><p>Among gynecologic malignancies, ovarian cancer is the third most common and the leading cause of cancer-related death in women. Epithelial ovarian carcinoma (EOC) accounts for more than 95% of all ovarian malignancies.[<xref rid="R1" ref-type="bibr">1</xref>] Approximately 75% of patients are diagnosed at an advanced stage, largely due to the asymptomatic nature of EOC, resulting in a 5-year survival rate of 20%&#8211;30%. Ovarian cancer is one of the most prevalent malignancies affecting women in India, and its incidence has been rising over the years.[<xref rid="R2" ref-type="bibr">2</xref>] The primary hereditary syndromes associated with ovarian cancer are the breast-ovarian cancer syndrome (BRCA), linked to mutations in the BRCA1 and BRCA2 tumor-suppressor genes, which increase the risk of both cancers, and the hereditary nonpolyposis colorectal cancer syndrome (Lynch syndrome), in which ovarian cancer occurs alongside nonpolyposis colorectal cancer, endometrial cancer, or both.[<xref rid="R3" ref-type="bibr">3</xref>] Due to late-stage diagnosis, the treatment of EOCs involves not only surgery but also an extended approach that includes chemotherapy and radiotherapy.</p><p>Immunotherapy has gained increasing attention in modern medicine due to its potential in treating cancers. It works through the mechanism of immune evasion, with anti-programmed cell death ligand 1 (PD-L1) and anti-programmed cell death 1 (PD-1) antibodies emerging as promising therapeutic agents. Anti-PD-1 and anti-PD-L1 treatments have been approved for several types of cancer, including non-small cell lung cancer (NSCLC), ovarian cancer, esophageal cancer, renal cell carcinoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.[<xref rid="R4" ref-type="bibr">4</xref>] The efficacy of immune checkpoint blockade with monoclonal antibodies in cancer treatment has been significant. Currently, immunotherapy is used for melanoma, NSCLC, and colorectal cancer.[<xref rid="R5" ref-type="bibr">5</xref>] Studies focusing on DNA repair genetics and tumor immune system interactions have significantly advanced the understanding of tumor biology. Over the last decade, substantial progress has been made in the development of checkpoint blockade immunotherapy, especially drugs targeting PD-1 and PD-L1. Notably, tumors with mismatch repair deficiency (dMMR) tend to show a better response to anti-PD-L1 therapy.[<xref rid="R6" ref-type="bibr">6</xref>]</p><p>The mismatch repair (MMR) pathway is responsible for correcting DNA replication errors, acting as a single-strand break repair mechanism that helps maintain DNA stability. Deficiency in MMR increases mutation rates by up to 1000-fold and is causally associated with the development of cancers such as colorectal, endometrial, ovarian, gastric cancers, and melanoma. However, it is important to note that not all tumors with dMMR respond to anti-PD-L1 therapy.</p><p>This study aims to evaluate the expression and relationship between PD-L1 and MMR status in EOCs within the Indian population, with the goal of identifying potential candidates for immunotherapy.</p></sec><sec sec-type="materials|methods"><title>M<sc>ATERIALS AND</sc> M<sc>ETHODS</sc></title><p>This study was conducted both retrospectively and prospectively, including resected specimens of ovarian carcinomas from the Department of Pathology at AIIMS, Jodhpur, covering the period from January 2016 to July 2020. Institutional review board approval was obtained at the commencement of the study (IEC number: AIIMS/IEC/2018/759). A total of 50 cases of EOC were included. Clinicopathological information collected included patient age, tumor histologic type, grade, stage, lymphovascular invasion (LVI), extra-ovarian spread, and tumor-infiltrating lymphocytes (TILs).</p><sec><title>Immunohistochemistry</title><p>PD-L1 expression in tumor cells and TILs as well as MMR status of the tumor were assessed using immunohistochemistry (IHC). Hematoxylin and eosin-stained slides were analyzed, and a representative section was selected for IHC. IHC for MMR staining was interpreted as positive when any nuclear staining within the tumor cells was observed. A complete absence of nuclear staining within the tumor cells, along with a concurrent positive internal control, was considered negative. Cases were classified as MMR retained if all four antibodies mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), MSH6, MLH3, postmeiotic segregation 1 (PMS1), or PMS2 showed positive nuclear staining in the tumor cells, and as MMR deficient (dMMR) if one or more antibodies showed an absence of nuclear staining in the tumor cells [<xref rid="jmh.jmh_102_25-f001" ref-type="fig">Figure 1</xref>].</p><fig position="float" id="jmh.jmh_102_25-f001" orientation="portrait"><label>Figure 1</label><caption><p>A case of high-grade serous carcinoma of the ovary (a) demonstrating programmed cell death ligand 1 expression in tumor cells and tumor-infiltrating lymphocytes (b). The tumor is mismatch repair stable and exhibits retained mutS homolog 2 (MSH-2) protein (c), retained MSH-6 protein (d), retained mutL homolog 1 protein (e), and retained postmeiotic segregation 2 protein (f)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JMH-16-309-g001.jpg"/></fig><p>PD-L1 immunohistochemical staining was interpreted as positive when clear membranous staining was present in &#8805;1% of tumor cells. A proportion score was assigned based on the extent of staining as follows: 1% to 5%, 6% to 10%, 11% to 25%, 26% to 50%, and &gt;50% [<xref rid="jmh.jmh_102_25-f001" ref-type="fig">Figure 1</xref>].</p><p>This rigorous approach allowed for a comprehensive analysis of the clinicopathological features and immunohistochemical profiles of EOCs, providing valuable insights into the prevalence and implications of PD-L1 expression and MMR deficiency (dMMR) in these tumors.</p><p>The Combined Positive Score (CPS) is a robust and reproducible PD-L1 scoring system. It is calculated as the ratio of the number of all PD-L1-expressing cells (including tumor cells, lymphocytes, and macrophages) to the number of all tumor cells. A CPS of 1 or greater is considered indicative of PD-L1 positivity. PD-L1 expression in tumor cells and TILs can help determine the potential benefit of anti-PD-L1 therapy in EOC. This approval underscores the importance of CPS in guiding treatment decisions and improving patient outcomes in these cancers.[<xref rid="R7" ref-type="bibr">7</xref>]</p></sec><sec><title>Statistical analysis</title><p>Qualitative data, such as PD-L1 expression and dMMR, were expressed as percentages. Data analysis was performed using the IBM SPSS version 23.0 (International Business Machines Corporation, Armonk, New York, United States), with inferential statistics conducted using the Fisher&#8217;s exact test.</p></sec></sec><sec sec-type="results"><title>R<sc>ESULTS</sc></title><p>Clinical and pathological parameters: The mean age of the patients was 52 years and 64% of the patient population was in the age group of over 50 years. Regarding tumor grading, 60% of the tumors were high-grade. Based on Pathological Tumor Nodes and Metastasis staging, 50% were stage III tumors, 44% were stage I tumors, and only 1 case was stage IV. The majority of the cases (88%) showed TILs [<xref rid="jmh.jmh_102_25-t001" ref-type="table">Table 1</xref>].</p><table-wrap position="float" id="jmh.jmh_102_25-t001" orientation="portrait"><label>Table 1</label><caption><p>Clinical and pathological parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Features</th><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Frequency (<italic toggle="yes">n</italic>=50), <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">&#8804;50</td><td align="center" rowspan="1" colspan="1">18 (36.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&gt;50</td><td align="center" rowspan="1" colspan="1">32 (64.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade</td><td align="left" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">20 (40.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">30 (60.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">22 (44.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">2 (4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">25 (50.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological diagnosis</td><td align="left" rowspan="1" colspan="1">Serous</td><td align="center" rowspan="1" colspan="1">40 (80.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mucinous</td><td align="center" rowspan="1" colspan="1">7 (14.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Endometrioid</td><td align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clear cell</td><td align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Malignant Brenner</td><td align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Extraovarian spread</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">21 (42.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">29 (58.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lympho-vascular invasion</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">44 (88.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">6 (12.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">TILs</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">7 (14.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">43 (86.0)</td></tr></tbody></table><table-wrap-foot><fn><p>TILs: Tumor-infiltrating lymphocytes</p></fn></table-wrap-foot></table-wrap><p>A statistically significant inverse association was found between TILs and the presence of LVI (<italic toggle="yes">P</italic> = 0.030). Tumors with increased TILs had a lower incidence of LVI. Out of 50 cases, 76% had a CPS of &lt;1%. CPS was &lt;1% in 86.2% of cases with extra-ovarian spread (<italic toggle="yes">P</italic> = 0.04). Only 20% of EOCs showed PD-L1 expression in tumor cells, and none of the cases had more than 25% PD-L1 expression in tumor cells. Extra-ovarian spread was more commonly observed in tumors that did not express PD-L1 in TILs (<italic toggle="yes">P</italic> = 0.044) and in tumor cells (<italic toggle="yes">P</italic> = 0.013) [<xref rid="jmh.jmh_102_25-t002" ref-type="table">Table 2</xref>].</p><table-wrap position="float" id="jmh.jmh_102_25-t002" orientation="portrait"><label>Table 2</label><caption><p>Extraovarian spread in combined positive score, programd cell death ligand 1 expression in tumor-infiltrating lymphocytes, and programmed cell death ligand expression in tumor cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Features</th><th align="center" rowspan="3" colspan="1">Characteristics (%)</th><th align="center" colspan="2" rowspan="1">Extra-ovarian spread</th><th align="center" rowspan="3" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" colspan="2" rowspan="1">
<hr/>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Present, (<italic toggle="yes">n</italic>=29), <italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Absent, (<italic toggle="yes">n</italic>=21), <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CPS</td><td align="center" rowspan="1" colspan="1">&lt;1</td><td align="center" rowspan="1" colspan="1">25 (86.2 )</td><td align="center" rowspan="1" colspan="1">13 (61.9)</td><td align="center" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#8805;1</td><td align="center" rowspan="1" colspan="1">4 (13.7)</td><td align="center" rowspan="1" colspan="1">8 (38.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PD-L1 expression in TILs (<italic toggle="yes">n</italic>=50)</td><td align="center" rowspan="1" colspan="1">&lt;5</td><td align="center" rowspan="1" colspan="1">27 (62.7)</td><td align="center" rowspan="1" colspan="1">16 (37.2)</td><td align="center" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5&#8211;10</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (100)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11&#8211;50</td><td align="center" rowspan="1" colspan="1">2 (66.6)</td><td align="center" rowspan="1" colspan="1">1 (33.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&gt;50</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PD-L1 expression in tumor cells (<italic toggle="yes">n</italic>=50)</td><td align="center" rowspan="1" colspan="1">&lt;1</td><td align="center" rowspan="1" colspan="1">27 (67.5)</td><td align="center" rowspan="1" colspan="1">13 (32.5)</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1&#8211;5</td><td align="center" rowspan="1" colspan="1">2 (22.2)</td><td align="center" rowspan="1" colspan="1">7 (77.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6&#8211;10</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11&#8211;25</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1 (100)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">26&#8211;50</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&gt;50</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>CPS: Combined positive score, PD-L1: Programmed cell death ligand 1, TILs: Tumor-infiltrating lymphocytes</p></fn></table-wrap-foot></table-wrap><p>The majority of PD-L1 expression in tumor cells (80%) was observed in lower stages of EOC [<xref rid="jmh.jmh_102_25-t003" ref-type="table">Table 3</xref>]. In contrast, PD-L1 expression in tumor cells was absent in most of the higher-stage EOC cases, with a statistically significant difference noted.</p><table-wrap position="float" id="jmh.jmh_102_25-t003" orientation="portrait"><label>Table 3</label><caption><p>Tumor stage and programmed cell death ligand expression in tumor cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Features</th><th align="center" colspan="2" rowspan="1">Stage</th><th align="center" rowspan="3" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" colspan="2" rowspan="1">
<hr/>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Lower stage (I and II), <italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Higher stage (III and IV), <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PD-L1 in tumor</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Present</td><td align="center" rowspan="1" colspan="1">8 (80)</td><td align="center" rowspan="1" colspan="1">2 (20)</td><td align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Absent</td><td align="center" rowspan="1" colspan="1">16 (40)</td><td align="center" rowspan="1" colspan="1">24 (60)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>PD-L1: Programmed cell death ligand 1</p></fn></table-wrap-foot></table-wrap><sec><title>Mismatch repair status</title><p>dMMR was identified in tumor cells in 30% (<italic toggle="yes">n</italic> = 15) of cases. TILs were present in 93.3% of cases with deficient MMR (dMMR). PD-L1 expression in TILs and tumor cells was absent in 80% and 86.6% of dMMR cases, respectively. PD-L1 expression in tumor cells was observed in only 2 of the 15 dMMR cases. LVI was absent in 80% of cases with dMMR [<xref rid="jmh.jmh_102_25-t004" ref-type="table">Table 4</xref>].</p><table-wrap position="float" id="jmh.jmh_102_25-t004" orientation="portrait"><label>Table 4</label><caption><p>Mismatch repair status in tumor-infiltrating lymphocytes, programmed cell death ligand 1 expression in tumor-infiltrating lymphocytes, programmed cell death ligand 1 expression in tumor cells, and lymphovascular invasion</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Features</th><th align="left" rowspan="3" colspan="1">Characteristics</th><th align="center" colspan="2" rowspan="1">MMR status total number of cases=50</th><th align="center" rowspan="3" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" colspan="2" rowspan="1">
<hr/>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Loss (<italic toggle="yes">n</italic>=15), <italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Retained (<italic toggle="yes">n</italic>=35), <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TILs</td><td align="left" rowspan="1" colspan="1">Absent (<italic toggle="yes">n</italic>=7)</td><td align="center" rowspan="1" colspan="1">1 (6.6)</td><td align="center" rowspan="1" colspan="1">6 (17.1)</td><td align="center" rowspan="1" colspan="1">0.659</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present (<italic toggle="yes">n</italic>=43)</td><td align="center" rowspan="1" colspan="1">14 (93.3)</td><td align="center" rowspan="1" colspan="1">29 (82.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PD-L1 expression in TILs</td><td align="left" rowspan="1" colspan="1">Absent (<italic toggle="yes">n</italic>=43)</td><td align="center" rowspan="1" colspan="1">12 (80.0)</td><td align="center" rowspan="1" colspan="1">31 (88.6)</td><td align="center" rowspan="1" colspan="1">0.415</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present (<italic toggle="yes">n</italic>=7)</td><td align="center" rowspan="1" colspan="1">3 (20.0)</td><td align="center" rowspan="1" colspan="1">4 (11.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PD-L1 expression in tumor cells</td><td align="left" rowspan="1" colspan="1">Absent (<italic toggle="yes">n</italic>=40)</td><td align="center" rowspan="1" colspan="1">13 (86.6)</td><td align="center" rowspan="1" colspan="1">27 (77.1)</td><td align="center" rowspan="1" colspan="1">0.702</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present (<italic toggle="yes">n</italic>=10)</td><td align="center" rowspan="1" colspan="1">2 (13.3)</td><td align="center" rowspan="1" colspan="1">8 (22.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lymphovascular invasion</td><td align="left" rowspan="1" colspan="1">Absent (<italic toggle="yes">n</italic>=44)</td><td align="center" rowspan="1" colspan="1">12 (80.0)</td><td align="center" rowspan="1" colspan="1">32 (91)</td><td align="center" rowspan="1" colspan="1">0.348</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Present (<italic toggle="yes">n</italic>=6)</td><td align="center" rowspan="1" colspan="1">3 (20.0)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>MMR: Mismatch repair, PD-L1: Programmed cell death ligand 1, TILs: Tumor-infiltrating lymphocytes</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>D<sc>ISCUSSION</sc></title><p>Among gynecological malignancies, ovarian carcinoma is the third most common cancer among women in India and has the worst prognosis.[<xref rid="R7" ref-type="bibr">7</xref>] All patients included in the study received adjuvant chemotherapy based on staging. Patients with stage IIIC and beyond received neo-adjuvant chemotherapy. Despite the availability of various treatment modalities, including surgery, chemotherapy, and radiotherapy, the 5-year survival rate of patients has not significantly improved. This has paved the way for the exploration of immunotherapy in ovarian carcinoma.</p><p>Among immunotherapies, PD-L1 serves as a checkpoint inhibitor that acts by identifying and eradicating the tumor cells. Tumors with a higher mutational load harbor more tumor-specific neoantigens, which stimulate the recruitment of an increased number of TILs. This is counterbalanced by the overexpression of immune checkpoint modulators such as PD-1 or PD-L1. This phenomenon explains the immunotherapeutic response of anti-PD-L1 drugs in MMR-deficient cases.[<xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref>]</p><p>The response to anti-PD-L1 therapy varies across different tumors. However, it has been reported that MMR-deficient tumors are more sensitive to anti-PD-L1 therapy, regardless of the primary site. Studies conducted by Sloan <italic toggle="yes">et al</italic>., Yamashita <italic toggle="yes">et al</italic>., Li <italic toggle="yes">et al</italic>., and Hacking <italic toggle="yes">et al</italic>. demonstrated a significant correlation between dMMR and PD-L1 expression in endometrial carcinomas.[<xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref><xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref>]</p><p>PD-L1 expression in tumor cells and TILs can help determine the potential benefit of anti-PD-L1 therapy in EOC. In the present study, 20% of EOC cases showed PD-L1 expression in tumor cells, while 14% of cases showed PD-L1 expression in TILs [<xref rid="jmh.jmh_102_25-f002" ref-type="fig">Figure 2</xref>]. PD-L1 expression in tumor cells was absent in the majority of advanced-stage tumors (stages III and IV) and in cases with extraovarian tumor spread. This suggests that PD-L1-expressing tumors are limited to the ovary and could serve as potential prognostic markers.</p><fig position="float" id="jmh.jmh_102_25-f002" orientation="portrait"><label>Figure 2</label><caption><p>A case of high-grade serous carcinoma of the ovary (a) showing the presence of programmed cell death ligand 1 (PD-L1) expression in tumor-infiltrating lymphocytes (TILs) and the absence of PD-L1 expression in tumor cells (b). The tumor is mismatch repair deficient, with retained mutS homolog 2 (MSH-2) protein (c) and MSH-6 protein (d), loss of mutL homolog 1 protein (e), and retained postmeiotic segregation 2 protein (f)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JMH-16-309-g002.jpg"/></fig><sec><title>Mismatch repair status</title><p>In our study, 15 out of 50 EOC cases (30%) demonstrated a loss of MMR proteins [<xref rid="jmh.jmh_102_25-f003" ref-type="fig">Figure 3</xref>]. MMR testing should be included in the routine IHC panel for EOC, as it plays a role in pathogenesis and guides patient selection for immunotherapy.</p><fig position="float" id="jmh.jmh_102_25-f003" orientation="portrait"><label>Figure 3</label><caption><p>A case of high-grade ovarian carcinoma (a) demonstrating the presence of programd cell death ligand 1 (PD-L1) expression in tumor-infiltrating lymphocytes (TILs) and the absence of PD-L1 expression in tumor cells (b). The tumor is mismatch repair deficient, showing loss of mutS homolog 2 (MSH-2) protein (c), retained MSH-6 protein (d), loss of mutL homolog 1 protein (e), and loss of postmeiotic segregation 2 protein (f)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JMH-16-309-g003.jpg"/></fig><p>The present study showed that dMMR cases were predominantly of higher stage, more frequently exhibited extraovarian spread, and were associated with the presence of TILs (<italic toggle="yes">P</italic> = 0.007). Although statistically insignificant, the majority of dMMR cases showed an absence of PD-L1 expression in tumor cells (86.7%) and TILs (80%).</p><p>Unlike endometrial carcinoma, where PD-L1 expression in tumor cells is higher in dMMR cases, no significant association was found between dMMR and PD-L1 expression in EOC.[<xref rid="R14" ref-type="bibr">14</xref>] Similarly, studies by Xiao <italic toggle="yes">et al</italic>. and Yamashita <italic toggle="yes">et al</italic>. also reported no significant correlation between dMMR and PD-L1 expression in tumor cells in ovarian carcinomas. This discrepancy may be attributed to the fact that MMR is retained in the majority of EOC cases (70%).[<xref rid="R11" ref-type="bibr">11</xref><xref rid="R15" ref-type="bibr">15</xref>]</p><p>Given the paucity of studies addressing the relationship between PD-L1 expression and MMR status in ovarian carcinomas, especially in India, the findings of our study provide valuable insights into the prognosis and the decision-making process regarding immunotherapy.</p></sec><sec><title>Limitations</title><p>This study was conducted on a small cohort of ovarian carcinoma cases at a single center. Therefore, the results cannot be generalized to other gynecological malignancies or populations. MMR status can be assessed through both IHC and polymerase chain reaction (PCR) testing, with PCR considered more accurate for detecting microsatellite instability. However, due to the unavailability of PCR, MMR status in this study was assessed solely through IHC.</p><p>Variations in PD-L1 expression in tumor cells in EOC observed across different studies may result from differences in the clones used for testing or inherent genetic and environmental factors among populations.</p></sec></sec><sec sec-type="conclusion"><title>C<sc>ONCLUSION</sc></title><p>PD-L1 expression was observed predominantly in early-stage ovarian tumors, suggesting a potential role for immunotherapeutic agents as a treatment modality. No significant association was found between dMMR status and PD-L1 expression in tumor cells in ovarian carcinomas. This study underscores the importance of routinely assessing PD-L1 expression and MMR status in tumor cells in ovarian carcinoma, as these markers provide critical information for patient management and prognosis.</p><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>R<sc>EFERENCES</sc></title><ref id="R1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Aysola</surname><given-names>K</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okoli</surname><given-names>C</given-names></name><name name-style="western"><surname>Hariprasad</surname><given-names>R</given-names></name><etal/></person-group><article-title>Epithelial ovarian cancer: An overview</article-title><source>World J Transl Med</source><year>2014</year><volume>3</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25525571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5528/wjtm.v3.i1.1</pub-id><pub-id pub-id-type="pmcid">PMC4267287</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Maheshwari</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name><name name-style="western"><surname>Mahantshetty</surname><given-names>U</given-names></name></person-group><article-title>Gynecological cancers: A summary of published Indian data</article-title><source>South Asian J Cancer</source><year>2016</year><volume>5</volume><fpage>112</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">27606294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2278-330X.187575</pub-id><pub-id pub-id-type="pmcid">PMC4991129</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Broaddus</surname><given-names>RR</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>HT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LM</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>MS</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>P</given-names></name><name name-style="western"><surname>Munsell</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16323174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.21560</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nebot-Bral</surname><given-names>L</given-names></name><name name-style="western"><surname>Brandao</surname><given-names>D</given-names></name><name name-style="western"><surname>Verlingue</surname><given-names>L</given-names></name><name name-style="western"><surname>Rouleau</surname><given-names>E</given-names></name><name name-style="western"><surname>Caron</surname><given-names>O</given-names></name><name name-style="western"><surname>Despras</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine</article-title><source>Eur J Cancer</source><year>2017</year><volume>84</volume><fpage>290</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">28846956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2017.07.026</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Willis</surname><given-names>BC</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>EA</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>KA</given-names></name><name name-style="western"><surname>Stoler</surname><given-names>MH</given-names></name><name name-style="western"><surname>Mills</surname><given-names>AM</given-names></name></person-group><article-title>Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium</article-title><source>Mod Pathol</source><year>2017</year><volume>30</volume><fpage>1622</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">28752845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2017.67</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kulangara</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Corigliano</surname><given-names>E</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>L</given-names></name><name name-style="western"><surname>Waldroup</surname><given-names>S</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer</article-title><source>Arch Pathol Lab Med</source><year>2019</year><volume>143</volume><fpage>330</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30028179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5858/arpa.2018-0043-OA</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Strickland</surname><given-names>KC</given-names></name><name name-style="western"><surname>Howitt</surname><given-names>BE</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>SA</given-names></name><name name-style="western"><surname>Rodig</surname><given-names>S</given-names></name><name name-style="western"><surname>Ritterhouse</surname><given-names>LL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>13587</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">26871470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.7277</pub-id><pub-id pub-id-type="pmcid">PMC4924663</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy</article-title><source>J Hematol Oncol</source><year>2019</year><volume>12</volume><fpage>54</fpage><pub-id pub-id-type="pmid">31151482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-019-0738-1</pub-id><pub-id pub-id-type="pmcid">PMC6544911</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sloan</surname><given-names>EA</given-names></name><name name-style="western"><surname>Ring</surname><given-names>KL</given-names></name><name name-style="western"><surname>Willis</surname><given-names>BC</given-names></name><name name-style="western"><surname>Modesitt</surname><given-names>SC</given-names></name><name name-style="western"><surname>Mills</surname><given-names>AM</given-names></name></person-group><article-title>PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including lynch syndrome-associated and MLH1 promoter hypermethylated tumors</article-title><source>Am J Surg Pathol</source><year>2017</year><volume>41</volume><fpage>326</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">27984238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000000783</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>H</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Sanuki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>5652</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">29464025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.23790</pub-id><pub-id pub-id-type="pmcid">PMC5814165</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Joehlin-Price</surname><given-names>AS</given-names></name><name name-style="western"><surname>Rhoades</surname><given-names>J</given-names></name><name name-style="western"><surname>Ayoola-Adeola</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K</given-names></name><name name-style="western"><surname>Parwani</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Programmed death ligand 1 expression among 700 consecutive endometrial cancers: Strong association with mismatch repair protein deficiency</article-title><source>Int J Gynecol Cancer</source><year>2018</year><volume>28</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">29053481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IGC.0000000000001120</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hacking</surname><given-names>S</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name><name name-style="western"><surname>Komforti</surname><given-names>M</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S</given-names></name><name name-style="western"><surname>Nasim</surname><given-names>M</given-names></name></person-group><article-title>MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (Sp 142) with potential therapeutic implications</article-title><source>Pathol Res Pract</source><year>2019</year><volume>215</volume><fpage>152552</fpage><pub-id pub-id-type="pmid">31353229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prp.2019.152552</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rajendran</surname><given-names>M</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Elhence</surname><given-names>PA</given-names></name><name name-style="western"><surname>Bharti</surname><given-names>JN</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>G</given-names></name><etal/></person-group><article-title>Expression of programmed cell death ligand-1 and mismatch repair status in endometrial carcinomas</article-title><source>J Midlife Health</source><year>2023</year><volume>14</volume><fpage>81</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">38029026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/jmh.jmh_6_23</pub-id><pub-id pub-id-type="pmcid">PMC10664048</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><name name-style="western"><surname>He</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yue</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer</article-title><source>Gynecol Oncol</source><year>2018</year><volume>149</volume><fpage>146</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">29496294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2018.02.009</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>